Free Trial

Oculis (OCS) Competitors

Oculis logo
$18.50 +0.07 (+0.38%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

OCS vs. VKTX, PTGX, MLTX, MTSR, KYMR, IMVT, MOR, CRNX, ALVO, and HCM

Should you be buying Oculis stock or one of its competitors? The main competitors of Oculis include Viking Therapeutics (VKTX), Protagonist Therapeutics (PTGX), MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), Kymera Therapeutics (KYMR), Immunovant (IMVT), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry.

Oculis vs. Its Competitors

Viking Therapeutics (NASDAQ:VKTX) and Oculis (NASDAQ:OCS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Viking Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -13,788.70%. Viking Therapeutics' return on equity of -14.41% beat Oculis' return on equity.

Company Net Margins Return on Equity Return on Assets
Viking TherapeuticsN/A -14.41% -14.02%
Oculis -13,788.70%-92.95%-70.03%

In the previous week, Viking Therapeutics had 6 more articles in the media than Oculis. MarketBeat recorded 10 mentions for Viking Therapeutics and 4 mentions for Oculis. Viking Therapeutics' average media sentiment score of 0.42 beat Oculis' score of 0.00 indicating that Viking Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Viking Therapeutics
6 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Neutral
Oculis
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

76.0% of Viking Therapeutics shares are owned by institutional investors. Comparatively, 22.3% of Oculis shares are owned by institutional investors. 4.1% of Viking Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Oculis has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Viking TherapeuticsN/AN/A-$109.96M-$1.15-27.21
Oculis$780K1,029.93-$97.43M-$2.64-6.97

Viking Therapeutics has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Oculis has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500.

Viking Therapeutics presently has a consensus target price of $87.15, suggesting a potential upside of 178.54%. Oculis has a consensus target price of $35.33, suggesting a potential upside of 92.03%. Given Viking Therapeutics' higher probable upside, equities research analysts clearly believe Viking Therapeutics is more favorable than Oculis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viking Therapeutics
0 Sell rating(s)
2 Hold rating(s)
10 Buy rating(s)
2 Strong Buy rating(s)
3.00
Oculis
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Viking Therapeutics beats Oculis on 12 of the 15 factors compared between the two stocks.

Get Oculis News Delivered to You Automatically

Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OCS vs. The Competition

MetricOculisMED IndustryMedical SectorNASDAQ Exchange
Market Cap$804.70M$2.96B$5.56B$9.04B
Dividend YieldN/A2.42%5.25%4.03%
P/E Ratio-6.978.0519.5820.23
Price / Sales1,029.93296.11442.27127.79
Price / CashN/A42.7337.5058.41
Price / Book9.637.748.085.60
Net Income-$97.43M-$54.96M$3.16B$248.43M
7 Day Performance-2.93%6.04%3.77%5.15%
1 Month Performance-7.02%4.47%3.90%7.62%
1 Year Performance64.29%6.12%34.22%21.56%

Oculis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OCS
Oculis
1.7453 of 5 stars
$18.40
-0.2%
$35.33
+92.0%
+67.4%$804.70M$780K-6.972News Coverage
VKTX
Viking Therapeutics
3.9825 of 5 stars
$27.51
-2.4%
$87.15
+216.8%
-43.9%$3.17BN/A-23.9220
PTGX
Protagonist Therapeutics
2.4803 of 5 stars
$49.87
-2.3%
$66.10
+32.5%
+51.6%$3.16B$434.43M66.49120News Coverage
Positive News
MLTX
MoonLake Immunotherapeutics
1.9544 of 5 stars
$47.50
-2.8%
$74.50
+56.8%
+7.5%$3.13BN/A-20.652News Coverage
Positive News
MTSR
Metsera
N/A$28.39
-3.6%
$55.00
+93.7%
N/A$3.09BN/A0.0081News Coverage
KYMR
Kymera Therapeutics
3.164 of 5 stars
$43.81
-2.2%
$59.11
+34.9%
+14.6%$2.92B$47.07M-14.13170Analyst Revision
IMVT
Immunovant
1.7315 of 5 stars
$16.42
-3.1%
$38.33
+133.5%
-41.8%$2.90BN/A-5.99120Analyst Forecast
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730
CRNX
Crinetics Pharmaceuticals
3.4517 of 5 stars
$29.06
-2.5%
$71.75
+146.9%
-33.0%$2.79B$1.04M-7.61210News Coverage
Analyst Forecast
ALVO
Alvotech
3.5074 of 5 stars
$9.02
-1.8%
$18.00
+99.6%
-27.2%$2.77B$491.98M24.381,032Trending News
HCM
HUTCHMED
1.7345 of 5 stars
$15.42
-2.5%
$19.00
+23.2%
-3.3%$2.76B$630.20M0.001,811

Related Companies and Tools


This page (NASDAQ:OCS) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners